RonaldLDrenglerMD

PubMed

• 560 citations
  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
  Amita Patnaik, S. Peter Kang, Drew W. Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Esp...> ;Clinical Cancer Research. 2015 May 14
• Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard ...
  Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow RG, Fine G, Choy GS, Azab M> ;J. Clin. Oncol.. 2011-05-20
• Tesetaxel: Development of a weekly dosing schedule for an oral advanced-generation taxane.
  Beeram M, Tolcher AW, Papadopoulos KP, Lang A, Smith L, Drengler R, Qureshi A, Patnaik A> ;J. Clin. Oncol.. 2011-05-20
• 7 citations
  Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies
  Y. Xu, Jill M. Kolesar, Larry J. Schaaf, Ronald Drengler, Wenrui Duan, Gregory A. Otterson, Charles L. Shapiro, John G. Kuhn, Miguel A. Villalona-Calero> ;Cancer Chemotherapy and Pharmacology. 2009 May 1
• ER alpha genotypes and breast cancer recurrence.
  Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G, Garner A, Cooper J, Pollock B, Kuhn J> ;J. Clin. Oncol.. 2008-05-20
• Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer.
  Drengler RL, Smith LS, Wood TE, Borad MJ, Ramanathan RK, Laheru DA, Hidalgo M, Von Hoff DD> ;J. Clin. Oncol.. 2008-05-20
• SPARC and CA19-9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine.
  Smith LS, Drengler RL, Wood TE, Laheru DA, Hidalgo M, Borad MJ, Trieu V, Knauer D, Desai N, Von Hoff DD> ;J. Clin. Oncol.. 2008-05-20
• Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment.
  Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Pollock BH, Kuhn JG> ;J. Clin. Oncol.. 2006-06-20
• 18 citations
  Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensiv...
  John D. Hainsworth, Donna Carrell, Ronald L. Drengler, Carroll Scroggin, F. Anthony Greco> ;Cancer. 2004 Jun 1
• 26 citations
  A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
  Lisa A. Hammond, John R. Eckardt, John G. Kuhn, Stanton L. Gerson, Thomas R. Johnson, Lon Smith, Ronald Drengler, Elizabeth Campbell, Geoffrey R. Weiss, Daniel D. Von ...> ;Clinical Cancer Research. 2004 Mar 1
• 42 citations
  Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced S...
  S. Gail Eckhardt, Sharyn D. Baker, Carolyn D. Britten, Manuel Hidalgo, Lillian L. Siu, Lisa A. Hammond, Miguel A. Villalona-Calero, Sally Felton, Ronald Drengler, John...> ;Journal of Clinical Oncology. 2000 Dec 15
• 6 citations
  Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer
  Amita Patnaik, Eric K. Rowinsky, Brinda K. Tammara, Manuel Hidalgo, Ronald Drengler, Allison M. Garner, Lillian L. Siu, Lisa A. Hammond, Sally Felton, Suresh Mallikaar...> ;Journal of Clinical Oncology. 2000 Dec 1
• 11 citations
  Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients wit...
  Leonel Ochoa, Herbert Hurwitz, George Wilding, Darrel P. Cohen, James P. Thomas, Garry Schwartz, P. Monroe, William P. Petros, V. Ph. Ertel, A. Hsieh, C. Hoffman, Rona...> ;Annals of Oncology. 2000 Oct 1
• 33 citations
  DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies
  Eric K. Rowinsky, Thomas R. Johnson, E C E Charles Geyer, Lisa A. Hammond, Gail G. Eckhardt, Ronald Drengler, Leslie Smetzer, John Coyle, Jinee Rizzo, Garry Schwartz, ...> ;Journal of Clinical Oncology. 2000 Sep 17
• 35 citations
  Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
  Carolyn D. Britten, Sharyn D. Baker, Louis Denis, Thomas E. Johnson, Ronald Drengler, Lillian L. Siu, Ken Duchin, John G. Kuhn, Eric K. Rowinsky> ;Clinical Cancer Research. 2000 Sep 1
• 24 citations
  Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies
  Manuel Hidalgo, Miguel A. Villalona-Calero, S. Gail Eckhardt, Ronald Drengler, Gladys Rodriguez, Lisa A. Hammond, Sami Diab, Geoffrey R. Weiss, Allison M. Garner, Eliz...> ;Journal of Clinical Oncology. 2000 Jan 1
• A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
  Miguel A. Villalona-Calero, Thierry Petit, John G. Kuhn, Patrick W. Cobb, Maura Kraynak, S. Gail Eckhardt, Ronald Drengler, Cecelia Simmons, Pedro Santabarbara, Daniel...> ;Clinical Cancer Research. 1999 Nov 1
• 64 citations
  Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies
  Miguel A. Villalona-Calero, Geoffrey R. Weiss, Howard A. Burris, Maura Kraynak, Gladys Rodrigues, Ronald Drengler, S. Gail Eckhardt, Bruno Reigner, Judy Moczygemba, Ha...> ;Journal of Clinical Oncology. 1999 Jun 1
• 55 citations
  Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
  S. Gail Eckhardt, Jinee Rizzo, Kevin R. Sweeney, Gillian F. Cropp, Sharyn D. Baker, Maura Kraynak, John G. Kuhn, Miguel A. Villalona-Calero, Lisa A. Hammond, Geoffrey ...> ;Journal of Clinical Oncology. 1999 Apr 1
• 78 citations
  Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors
  Ronald Drengler, John G. Kuhn, Larry J. Schaaf, Gladys Rodriguez, Miguel A. Villalona-Calero, Lisa A. Hammond, Joseph A. Stephenson, Stephanie Hodges, Maura Kraynak, B...> ;Journal of Clinical Oncology. 1999 Feb 1
• 4 citations
  A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
  Sami Diab, Sharyn D. Baker, Amita S. Joshi, Howard A. Burris, Patrick W. Cobb, Miguel A. Villalona-Calero, S. Gail Eckhardt, Geoffrey R. Weiss, Gladys Rodriguez, Ronal...> ;Clinical Cancer Research. 1999 Feb 1
• 109 citations
  Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR...
  Eric K. Rowinsky, Lon Smith, Yufeng Wang, P Chaturvedi, M Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, Lisa A. Hammond, Maura Kraynak, Ronald Drengler, J. St...> ;Journal of Clinical Oncology. 1998 Sep 1
• 13 citations
  Alternative dosing schedules for irinotecan.
  Mace L. Rothenberg, J. G. Kuhn, Larry J. Schaaf, Ronald Drengler, S. G. Eckhardt, Miguel A. Villalona-Calero, Lisa A. Hammond, Langdon L. Miller, Petit Rg, Eric K. Row...> ;Oncology. 1998 Aug 1
• 1 citations
  DOCETAXEL IN COMBINATION WITH FLUOROURACIL : STUDY DESIGN AND PRELIMINARY RESULTS
  E. K. Rowinsky, Lon Smith, Gladys Rodriguez, L White, Ronald Drengler, D. Von Hoff, N. W. Peacock, C. Aylesworth, H. A. Burris, Peter M. Ravdin, Robert E. Bellet> ;Oncology. 1997 Jun 1
• 26 citations
  A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema
  M. A. Villalona-Calero, Jeffrey J. Eckardt, Howard A. Burris, Maura Kraynak, S. Fields-Jones, Carlos Bazan, Jack L. Lancaster, T. Hander, R. Goldblum, Lisa A. Hammond,...> ;Annals of Oncology. 1998 Jan 1
• Join now to see all